Gilead Sciences Current Ratio 2006-2021 | GILD
For a detailed definition, formula and example for Current Ratio, check out our new background page here.
Current and historical current ratio for Gilead Sciences (GILD) from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Gilead Sciences current ratio for the three months ending June 30, 2021 was 1.36.
| Gilead Sciences Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2021-06-30 |
$13.93B |
$10.21B |
1.36 |
| 2021-03-31 |
$13.28B |
$9.71B |
1.37 |
| 2020-12-31 |
$16.00B |
$11.40B |
1.40 |
| 2020-09-30 |
$30.93B |
$9.51B |
3.25 |
| 2020-06-30 |
$24.64B |
$10.56B |
2.33 |
| 2020-03-31 |
$26.95B |
$8.88B |
3.04 |
| 2019-12-31 |
$30.30B |
$9.76B |
3.10 |
| 2019-09-30 |
$28.36B |
$9.57B |
2.96 |
| 2019-06-30 |
$33.73B |
$8.96B |
3.76 |
| 2019-03-31 |
$34.02B |
$9.40B |
3.62 |
| 2018-12-31 |
$35.84B |
$10.61B |
3.38 |
| 2018-09-30 |
$34.92B |
$10.12B |
3.45 |
| 2018-06-30 |
$32.73B |
$10.91B |
3.00 |
| 2018-03-31 |
$30.26B |
$10.67B |
2.84 |
| 2017-12-31 |
$31.82B |
$11.64B |
2.74 |
| 2017-09-30 |
$35.32B |
$9.60B |
3.68 |
| 2017-06-30 |
$28.59B |
$8.49B |
3.37 |
| 2017-03-31 |
$21.42B |
$8.28B |
2.59 |
| 2016-12-31 |
$19.59B |
$9.22B |
2.13 |
| 2016-09-30 |
$21.43B |
$11.07B |
1.94 |
| 2016-06-30 |
$18.35B |
$10.44B |
1.76 |
| 2016-03-31 |
$19.27B |
$10.91B |
1.77 |
| 2015-12-31 |
$24.76B |
$9.89B |
2.50 |
| 2015-09-30 |
$25.91B |
$9.36B |
2.77 |
| 2015-06-30 |
$18.09B |
$8.93B |
2.03 |
| 2015-03-31 |
$20.06B |
$7.43B |
2.70 |
| 2014-12-31 |
$17.71B |
$5.76B |
3.08 |
| 2014-09-30 |
$12.56B |
$6.06B |
2.08 |
| 2014-06-30 |
$15.50B |
$6.23B |
2.49 |
| 2014-03-31 |
$12.97B |
$5.92B |
2.19 |
| 2013-12-31 |
$7.00B |
$6.41B |
1.09 |
| 2013-09-30 |
$6.97B |
$4.90B |
1.42 |
| 2013-06-30 |
$7.07B |
$4.94B |
1.43 |
| 2013-03-31 |
$6.66B |
$4.29B |
1.55 |
| 2012-12-31 |
$6.16B |
$4.24B |
1.45 |
| 2012-09-30 |
$5.88B |
$4.80B |
1.23 |
| 2012-06-30 |
$5.84B |
$4.99B |
1.17 |
| 2012-03-31 |
$5.83B |
$4.19B |
1.39 |
| 2011-12-31 |
$13.92B |
$2.52B |
5.54 |
| 2011-09-30 |
$6.15B |
$2.22B |
2.76 |
| 2011-06-30 |
$6.22B |
$2.31B |
2.69 |
| 2011-03-31 |
$6.85B |
$2.77B |
2.47 |
| 2010-12-31 |
$5.71B |
$2.47B |
2.32 |
| 2010-09-30 |
$6.03B |
$2.59B |
2.33 |
| 2010-06-30 |
$5.71B |
$3.11B |
1.84 |
| 2010-03-31 |
$5.12B |
$1.89B |
2.72 |
| 2009-12-31 |
$4.81B |
$1.87B |
2.57 |
| 2009-09-30 |
$4.30B |
$1.89B |
2.28 |
| 2009-06-30 |
$4.00B |
$1.78B |
2.25 |
| 2009-03-31 |
$4.62B |
$1.26B |
3.66 |
| 2008-12-31 |
$4.28B |
$1.22B |
3.50 |
| 2008-09-30 |
$4.33B |
$1.26B |
3.44 |
| 2008-06-30 |
$3.67B |
$2.45B |
1.50 |
| 2008-03-31 |
$2.95B |
$0.94B |
3.14 |
| 2007-12-31 |
$3.03B |
$0.74B |
4.11 |
| 2007-09-30 |
$2.55B |
$0.69B |
3.68 |
| 2007-06-30 |
$2.45B |
$0.75B |
3.26 |
| 2007-03-31 |
$2.44B |
$0.71B |
3.44 |
| 2006-12-31 |
$2.43B |
$0.76B |
3.18 |
| 2006-09-30 |
$4.03B |
$0.58B |
6.93 |
| 2006-06-30 |
$2.49B |
$0.51B |
4.91 |
| 2006-03-31 |
$3.38B |
$0.42B |
8.00 |
| 2005-12-31 |
$3.09B |
$0.47B |
6.65 |
| 2005-09-30 |
$2.30B |
$0.27B |
8.58 |
| 2005-06-30 |
$2.39B |
$0.26B |
9.13 |
| 2005-03-31 |
$2.07B |
$0.27B |
7.66 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$89.497B |
$24.689B |
|
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
|
